SPARC (SECRETED PROTEIN, ACIDIC AND RICH IN CYSTEINE), A NEW TARGET FOR THE TREATMENT AND PREVENTION OF ACUTE LIVER FAILURE

摘要

The invention relates to the identification of Secreted Protein, Acidic and Rich in Cysteine (SPARC) as a new therapeutic target in patients with fulminant hepatitis and allows the development of a strategy destined to protect the liver form damage. The invention relates to the treatment of acute liver failure or fulminant hepatitis by administering to a subject in need thereof an agent that inhibits at least partially the expression of SPARC and/or interferes with its biological function.